Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs.
Four polyvinyl chloride (PVC) matrix membrane electrodes responsive to 2 drugs affecting the urogenital system--oxybutynin hydrochloride (OX) and flavoxate hydrochloride (FX)--were developed, described, and characterized. A precipitation-based technique with tungstophosphate (TP) and ammonium reineckate (R) anions as electroactive materials in a PVC matrix with an OX cation was used for electrode 1 and 2 fabrication, respectively. Electrode 3 and 4 fabrication was based on use of the precipitation technique of FX cation with tetrakis (4-chlorophenyl) borate and R anions as electroactive materials. Fast and stable Nernstian responses in the range 1 x 10(-2)-1 x 10(-6) M for the 2 drugs over the pH range 5-8 revealed the performance characteristics of these electrodes, which were evaluated according to International Union of Pure and Applied Chemistry recommendations. The method was applied to FX and OX in their pharmaceutical formulations and in human plasma samples. The 4 proposed sensors were found to be specific for the drugs in the presence of up to 60% of their degradation products. Validation of the method according to the quality assurance standards showed suitability of the proposed electrodes for use in the quality control assessment of these drugs. The recoveries for determination of the drugs by the 4 proposed selective electrodes were 99.5 +/- 0.5, 100.0 +/- 0.4, 99.9 +/- 0.4, and 100.1 +/- 0.4% for sensors 1-4, respectively. Statistical comparison between the results obtained by this method and the official method of the drugs was done, and no significant difference found.
Heba
Mohamed
M
Cairo University, Faculty of Pharmacy, Analytical Chemistry, Kasr Al-Ainy 11652, Cairo, Egypt. bebo77_7777@yahoo.com
Ramadan
Nesrin
N
El-Laithy
Moustafa
M
D002138:Calibration; D004338:Drug Combinations; D004566:Electrodes; D005422:Flavoxate / Q000008:administration & dosage / Q000032:analysis*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007202:Indicators and Reagents; D008333:Mandelic Acids / Q000008:administration & dosage / Q000032:analysis*; D013058:Mass Spectrometry; D008567:Membranes, Artificial; D010276:Parasympatholytics / Q000008:administration & dosage / Q000032:analysis*; D019999:Pharmaceutical Solutions / Q000032:analysis; D011108:Polymers; D011199:Potentiometry; D012015:Reference Standards; D013055:Spectrophotometry, Infrared; D013607:Tablets; D013608:Tablets, Enteric-Coated / Q000032:analysis; D013696:Temperature; D014566:Urogenital System
D004338:Drug Combinations; D007202:Indicators and Reagents; D008333:Mandelic Acids; D008567:Membranes, Artificial; D010276:Parasympatholytics; D019999:Pharmaceutical Solutions; D011108:Polymers; D013607:Tablets; D013608:Tablets, Enteric-Coated; D005422:Flavoxate; C005419:oxybutynin